Matthew Norawong
Matthew is a senior manager on PhRMA’s Public Affairs team focusing on Medicare, Medicaid, importation and more. Prior to coming to PhRMA, he previously worked as a health policy analyst for National Journal’s Network Science Initiative, primarily supporting companies in the life sciences industry. Matthew completed his undergraduate studies in political science at the University of Washington and subsequently earned a Master of Public Health from the George Washington University. A native of the Pacific Northwest, Matthew currently resides in Washington, DC. Outside of the office, Matthew is an avid runner and enjoys playing bass guitar with his indie rock band.
Medicare Part D at 20: Building on a strong foundation
Patients speak out: MFN won't address my affordability concerns
MFN price controls threaten American jobs and the U.S. economy
CMS undermines medical progress with MFN price controls
Policymakers shouldn’t double down on the IRA’s flaws with MFN
Insurers routinely block seniors’ access to medicines in Medicare Part D
MFN undermines U.S. biopharmaceutical innovation
The IRA’s price setting doesn’t guarantee lower costs or better access
What seniors can expect this open enrollment
Part D premiums are going up, while choices are going down
CMS continues to make a bad law worse
Ensuring access to affordable medicines for patients through Medicaid
How the IRA is impacting the generic drug market
CMS, don’t fall behind the rest of the medical community on obesity
The real cost of denying access to medicines in Medicaid
Patients are losing as government price setting continues
The Patient Perspective: Vaccines
New Report: Tackling chronic conditions with preventive treatment
New Report: Vaccines continue to drive improved health outcomes
ICYMI: What patients care about this election year
New Report: 1,600 cancer treatments and vaccines in clinical development
A conversation with Dr. Mike Ybarra on the current state of COVID-19
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
New Report: Nearly 800 medicines in development to treat chronic conditions
ICYMI: Patients across the country are sharing concerns about government price setting
Word of the Month: Biomarkers and surrogate endpoints
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Ensuring timely reauthorization of PDUFA and BsUFA
Matthew Norawong